Vitamin D treatment in primary hyperparathyroidism: a randomized placebo controlled trial.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc in the context of hyperparathyroidism, published as a randomized controlled trial.

However, concerns have been raised about the safety of vitamin D supplementation in PHPT.

Who Took Part

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and parallel-group study.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

Blinding on both sides kept the participants and researchers unaware of who received Vitamin D, K2, Magnesium and Zinc.

Some participants received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.

The Vitamin D, K2, Magnesium and Zinc group and the comparison group ran side by side rather than switching.

This was an investigator-initiated double-blind, randomized, placebo-controlled, parallel-group trial from a single center.

What Was Measured

Topics PubMed links to this paper include Bone Density, Calcium, Cholecalciferol, Hyperparathyroidism, Parathyroid Hormone, Phosphates and Vitamin D.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in people with hyperparathyroidism.

Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2014 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, Hyperparathyroidism research.